NCT05166707: An overdue trial by BIXINK Therapeutics Co., Ltd.
This trial is overdue. It was due to report 2 years ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT05166707 |
|---|---|
| Title | A Prospective, Single Arm, Open, Single-center, Feasibility Study to Assess the Effectiveness and Safety of Mobile App (OC Free) for Patients With Obsessive-Compulsive Disorder (OCD) |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 18, 2021 |
| Completion date | Nov. 18, 2022 |
| Required reporting date | Nov. 18, 2023, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 3, 2025 |
| Days late | 746 |